# Campath-1H + FK506 and Methylprednisolone for GVHD

> **NCT00109993** · PHASE2 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 34 (actual)

## Conditions studied

- Breast Cancer
- Chronic Myeloproliferative Disorders
- Gestational Trophoblastic Tumor
- Graft Versus Host Disease
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Diseases
- Neuroblastoma
- Ovarian Cancer
- Testicular Germ Cell Tumor

## Interventions

- **BIOLOGICAL:** alemtuzumab
- **DRUG:** methylprednisolone
- **DRUG:** tacrolimus

## Key facts

- **NCT ID:** NCT00109993
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2006-06
- **Final completion:** 2007-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2010-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00109993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00109993, "Campath-1H + FK506 and Methylprednisolone for GVHD". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00109993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*